Ann: Q4 2021 quarterly activity and cash flow report, page-38

I'd be surprised if it was the intention of the current board to take NNZ-2566 all the way.

With the Acadia deal, NEU punted that trofinetide would pass phase 3.

Now should have been the time to be seeking a buyer for the company. But potential purchasers have known that and hence the SP manipulation.

One thing NEU does have going for it right now is that a suitor for the company would not want the ROW rights given to a competitor.

The cleanest solution is that ACAD gets ROW setting up both companies to be taken out together down the track.

I'm positive Baker Bros will eventually sell ACAD, but the SP was smashed a little while back when their primary drug clipped a hurdle.

As a long term investor, I'm with LT, only a little higher than $8. Look for an offer to come on FDA approval.